Back to Search
Start Over
Pretransplant Hepatic Malignancy Increases Risk of De Novo Malignancy after Liver Transplantation.
- Source :
-
Journal of Korean medical science [J Korean Med Sci] 2020 Mar 23; Vol. 35 (11), pp. e69. Date of Electronic Publication: 2020 Mar 23. - Publication Year :
- 2020
-
Abstract
- Background: Hepatocellular carcinoma (HCC) recurrence and development of de novo malignancy (DNM) after liver transplantation (LT) are the major causes of late recipient death.<br />Methods: We analyzed the incidence of extrahepatic DNM following living donor LT according to the status of pretransplant hepatic malignancy. We selected 2,076 adult patients who underwent primary LDLT during 7 years from January 2010 to December 2016.<br />Results: The pretransplant hepatic malignancy group (n = 1,012) showed 45 cases (4.4%) of the following extrahepatic DNMs: posttransplant lymphoproliferative disease (PTLD) in 10; lung cancer in 10; stomach cancer in 6; colorectal cancer in 5; urinary bladder cancer in 3; and other cancers in 11. The pretransplant no hepatic malignancy group (n = 1,064) showed 25 cases (2.3%) of the following extrahepatic DNMs: colorectal cancer in 3; stomach cancer in 3; leukemia in 3; lung cancer in 3; PTLD in 2; prostate cancer in 2; and other cancers in 9. Incidences of extrahepatic DNM in the pretransplant hepatic malignancy and no hepatic malignancy groups were as follows: 1.1% and 0.5% at 1 year, 3.2% and 2.0% at 3 years, 4.6% and 2.5% at 5 years, and 5.4% and 2.8% at 8 years, respectively ( P = 0.006). Their overall patient survival rates were as follows: 97.3% and 97.2% at 1 year, 91.6% and 95.9% at 3 years, 89.8% and 95.4% at 5 years, and 89.2% and 95.4% at 8 years, respectively ( P < 0.001). Pretransplant hepatic malignancy was the only significant risk factor for posttransplant extrahepatic DNM.<br />Conclusion: Our results suggest that patients who had pretransplant hepatic malignancy be followed up more strictly because they have a potential risk of primary hepatic malignancy recurrence as well as a higher risk of extrahepatic DNM than patients without pretransplant hepatic malignancy.<br />Competing Interests: The authors have no potential conflicts of interest to disclose.<br /> (© 2020 The Korean Academy of Medical Sciences.)
Details
- Language :
- English
- ISSN :
- 1598-6357
- Volume :
- 35
- Issue :
- 11
- Database :
- MEDLINE
- Journal :
- Journal of Korean medical science
- Publication Type :
- Academic Journal
- Accession number :
- 32193900
- Full Text :
- https://doi.org/10.3346/jkms.2020.35.e69